Core Insights - The United States Patent and Trademark Office (USPTO) has issued Patent No. US 12,343,315 B2 to Avicanna Inc. for its topical cannabinoid compositions aimed at promoting clear skin [1][2] - The patent covers a topical gel formulation that combines cannabinoids with antioxidants, anti-microbial agents, and anti-inflammatory agents, targeting skin diseases such as acne, wrinkles, rosacea, and erythema [2] - Avicanna's CEO expressed enthusiasm about the patent, highlighting its potential in the company's commercial platforms and pharmaceutical pipeline [3] Company Overview - Avicanna is a biopharmaceutical company focused on developing, manufacturing, and commercializing plant-derived cannabinoid-based products for the medical and pharmaceutical markets [4] - The company has a robust scientific platform that includes R&D and clinical development, leading to over thirty proprietary, evidence-based finished products [4] - Avicanna operates multiple business pillars, including a medical cannabis formulary (RHO Phyto™), a medical cannabis care platform (MyMedi.ca), a pharmaceutical pipeline, and a subsidiary (Santa Marta Golden Hemp SAS) that supplies active pharmaceutical ingredients [4][7]